1. Emerging Targeted Therapies for NSCLC

2. Current Molecular Characterization

3. Overview of Approved Therapies

4. FLAURA: Final OS

5. Combining EGFR TKI and an Anti-Angiogenic

6. ASCEND-7: Ceritinib in Patients With CNS Disease

7. ALEX: Final PFS

8. Blood First Assay Screening Trial (BFAST)

9. Emerging RET Inhibitor: BLU-667

10. Emerging KRAS Inhibitor: AMG 510

11. Emerging MET Inhibitor: Tepotinib

12. Emerging HER2 Inhibitor: ZW25

13. Afatinib Activity in NRG1 Fusion-Positive NSCLC Cases

14. Updates to NTRK Inhibitor: Larotrectinib

15. Emerging NTRK/ROS1 Inhibitor: Repotrectinib

16. Updates to NTRK/ROS1 Inhibitor: Entrectinib

17. Clinical Impact of Emerging Targets and Treatments

18. Comments on the Cost of Molecular Testing

19. Key Takeaways

20. Looking Forward to 2020

21. Abbreviations

22. Abbreviations (cont)